SNDX – syndax pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at JPMorgan Chase & Co. from $33.00 to $38.00. They now have an "overweight" rating on the stock.
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at Citigroup Inc. from $37.00 to $45.00. They now have a "buy" rating on the stock.
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) had its price target raised by analysts at HC Wainwright from $49.00 to $51.00. They now have a "buy" rating on the stock.
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation [Yahoo! Finance]
Form 8-K Syndax Pharmaceuticals For: Nov 15
Form 8-K Syndax Pharmaceuticals For: Nov 12
Form SC 13G/A Syndax Pharmaceuticals Filed by: BlackRock, Inc.
Form SC 13G/A Syndax Pharmaceuticals Filed by: WELLINGTON MANAGEMENT GROUP LLP
Form 10-Q Syndax Pharmaceuticals For: Sep 30
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.